SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

Recruiting Observational Study
Parkinson Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
90 (estimated)
Sponsor
Bial - Portela C S.A. · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titrat…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * The patient is ≥ 18 years of age. * The patient has a clinical diagnosis of idiopathic Parkinson's disease. * The patient will initiate SL-APO for the treatment of OFF episodes according to the SmPC. * The patient is not currently on titration or maintenance dose for SL-APO. *…
Contacts

Ruben Arnelas

+351229866100

clinical.trials@bial.com

CONTACT